UBS Group
NVO

UBS Group’s Novo Nordisk NVO Stock Holding History

UBS Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.9M Sell
1,229,296
-789,922
-39% -$33.9M 0.01% 1587
2026
Q1 		$74.2M Buy
2,019,218
+1,166,180
+137% +$55.3M 0.01% 1276
2025
Q4 		$43.4M Sell
853,038
-30,748
-3% -$1.57M 0.01% 1759
2025
Q3 		$49M Buy
883,786
+541,284
+158% +$31.7M 0.01% 1638
2025
Q2 		$23.6M Sell
342,502
-197,872
-37% -$13.5M ﹤0.01% 2203
2025
Q1 		$37.5M Buy
540,374
+415,656
+333% +$34.3M 0.01% 1732
2024
Q4 		$10.7M Buy
124,718
+120,200
+2,660% +$13M ﹤0.01% 2959
2024
Q3 		$538K Sell
4,518
-15,482
-77% -$2.06M ﹤0.01% 5177
2024
Q2 		$2.85M Sell
20,000
-17,500
-47% -$2.32M ﹤0.01% 3396
2024
Q1 		$4.82M Sell
37,500
-207,288
-85% -$24.7M ﹤0.01% 3013
2023
Q4 		$25.3M Buy
+244,788
New +$24.2M 0.01% 1426
2022
Q1 		– Sell
-127,800
Closed -$7.16M – 10694
2021
Q4 		$7.16M Buy
+127,800
New +$6.92M ﹤0.01% 2460
2020
Q3 		– Sell
-16,000
Closed -$524K – 8280
2020
Q2 		$524K Hold
16,000
– – ﹤0.01% 4090
2020
Q1 		$482K Buy
+16,000
New +$476K ﹤0.01% 3989
2019
Q1 		– Sell
-132,200
Closed -$3.04M – 8019
2018
Q4 		$3.04M Buy
132,200
+86,000
+186% +$1.91M ﹤0.01% 2623
2018
Q3 		$1.09M Buy
+46,200
New +$1.13M ﹤0.01% 3770
2018
Q1 		– Sell
-181,800
Closed -$4.88M – 8058
2017
Q4 		$4.88M Buy
+181,800
New +$4.62M ﹤0.01% 2376
2015
Q1 		– Sell
-2,000
Closed -$42K – 9172
2014
Q4 		$42K Buy
+2,000
New +$44.7K ﹤0.01% 6702

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Group's NVO Position: Q2 2026 in Review

UBS Group reduced its Novo Nordisk (NVO) stake by 13% in Q2 2026, selling an estimated $25M and leaving 3,984,940 shares worth $191M. The position accounts for 0.02% of the portfolio, ranked #694.

UBS Group first reported a position in NVO in Q4 2014 and has held it in 47 quarters since. The position peaked at $250M in Q4 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • UBS Group held 3,984,940 shares of Novo Nordisk worth $191M as of Q2 2026.
  • UBS Group sold 580,768 Novo Nordisk shares in Q2 2026, an estimated $25M.
  • Novo Nordisk made up 0.02% of UBS Group's portfolio in Q2 2026, its #694 holding.
  • UBS Group first reported a position in Novo Nordisk in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Novo Nordisk position peaked at $250M in Q4 2025.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.